Nov 21 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Friday it plans to roll out an employer-focused obesity care model early next year, aiming to expand access to its blockbuster weight-loss ...
Still, kickstarting your fitness journey does not have to necessarily be a mammoth undertaking. It's about giving yourself time to build a habit and then allowing that habit the space to accommodate ...
(Reuters) -Eli Lilly said on Friday it plans to roll out an employer-focused obesity care model early next year, aiming to expand access to its blockbuster weight-loss drug through partnerships with ...
New subgroup analysis from the Phase 3 monarchE trial that explores outcomes by nodal status for Verzenio plus endocrine therapy in HR+, HER2– high-risk early breast cancer INDIANAPOLIS, Nov. 24, 2025 ...
Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks. Eli Lilly achieved a $1 trillion market cap, a healthcare first, ...
Nov 13 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab and Eli Lilly (LLY.N), opens new tab denied weight-loss drug partnership with Mangoceuticals (MGRX.O), opens new tab on Thursday, hours after ...
Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump administration regarding the sale of its GLP-1 medication. In a letter to Lilly ...
Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific antibodies. ABL Bio will receive an upfront payment and potential milestone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback